Aquestive Therapeutics Q1 2025 10-Q Filed
Ticker: AQST · Form: 10-Q · Filed: May 12, 2025 · CIK: 1398733
| Field | Detail |
|---|---|
| Company | Aquestive Therapeutics, Inc. (AQST) |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, equity, pharmaceuticals
TL;DR
Aquestive Therapeutics Q1 2025 10-Q is in: Equity changes and ATM offering details disclosed.
AI Summary
Aquestive Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results for the first quarter of 2025, detailing changes in its equity accounts, including common stock and additional paid-in capital, particularly related to at-the-market offerings. The filing also includes information on its business operations and financial condition.
Why It Matters
This filing provides investors with the latest financial performance and operational updates for Aquestive Therapeutics, crucial for understanding the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — The filing contains standard financial disclosures for a public company, but the nature of pharmaceutical development and market performance introduces inherent risks.
Key Numbers
- 2025-03-31 — Reporting Period End (Quarterly financial data is as of this date.)
- 2025-05-12 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Aquestive Therapeutics, Inc. (company) — Filer
- 20250331 (date) — Reporting Period End Date
- 20250512 (date) — Filing Date
- MonoSol Rx, Inc. (company) — Former Company Name
FAQ
What were the key changes in Aquestive Therapeutics' equity accounts during the first quarter of 2025?
The filing indicates changes in us-gaap:CommonStockMember, us-gaap:AdditionalPaidInCapitalMember, and us-gaap:RetainedEarningsMember, particularly related to aqst:AtTheMarketOfferingMember during the period from January 1, 2025, to March 31, 2025.
What is the fiscal year end for Aquestive Therapeutics?
Aquestive Therapeutics' fiscal year ends on December 31.
What was Aquestive Therapeutics' former company name?
The former company name was MonoSol Rx, Inc., with a date of name change on May 7, 2007.
What is the primary business address for Aquestive Therapeutics?
The business address is 30 Technology Drive, Warren, NJ 07059.
What is the SIC code for Aquestive Therapeutics?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Aquestive Therapeutics, Inc. (AQST).